Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?

Trends in Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 92-100

  Cavone, Leonardo ^a   Chiarugi, Alberto ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

AUTOIMMUNITY; CELL DEATH; CENTRAL NERVOUS SYSTEM; CYTOKINE RELEASE; DEMYELINATION; DNA BINDING; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHADENITIS; LYMPHOCYTIC INFILTRATION; MULTIPLE SCLEROSIS; NERVE CELL LESION; NEUROIMMUNOLOGY; NEUROPROTECTION; NONHUMAN; REVIEW;

ANIMALS; ENZYME INHIBITORS; HUMANS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; POLY(ADP-RIBOSE) POLYMERASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84856651114     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.10.002     Document Type: Review

References (95)

1. Greer J.M., McCombe P.A. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J. Neuroimmunol. 2011, 234:7-18.
2. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996, 46:907-911.
3. Ramagopalan S.V., et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010, 9:727-739.
4. Miller S.D., et al. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 2007, 1103:179-191.
5. Gandhi R., et al. Role of the innate immune system in the pathogenesis of multiple sclerosis. J. Neuroimmunol. 2010, 221:7-14.
6. Kim J.M., et al. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
7. Huynh T. The multiple sclerosis market. Nat. Rev. Drug Discov. 2010, 9:759-760.
8. Racke M.K., Lovett-Racke A.E. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J. Immunol. 2011, 186:1887-1890.
9. Rudick R.A., Goelz S.E. Beta-interferon for multiple sclerosis. Exp. Cell Res. 2011, 317:1301-1311.
10. Gawronski K.M., et al. Treatment options for multiple sclerosis: current and emerging therapies. Pharmacotherapy 2010, 30:916-927.
11. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 2011, 25:37-52.
12. Keene D.L., et al. Monoclonal antibodies and progressive multifocal leukoencephalopathy. Can. J. Neurol. Sci. 2011, 38:565-571.
13. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
14. Hottiger M.O., et al. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35:208-219.
15. Rouleau M., et al. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer 2010, 10:293-301.
16. Schreiber V., et al. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
17. Gagne J.P., et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res. 2008, 36:6959-6976.
18. Ahel I., et al. Poly(ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 2008, 451:81-85.
19. Timinszky G., et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nat. Struct. Mol. Biol. 2009, 16:923-929.
20. Tong W.M., et al. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim. Biophys. Acta 2001, 1552:27-37.
21. Chiarugi A. PARP-1: killer or conspirator? The suicide hypothesis revisited. Trends Pharmacol. Sci 2002, 23:122-129.
22. Wang Y., et al. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 2009, 218:193-202.
23. Kauppinen T.M., Swanson R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007, 145:1267-1272.
24. Kauppinen T.M. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease. Neurochem. Int. 2007, 50:954-958.
25. Potaman V.N., et al. Specific binding of poly(ADP-ribose) polymerase-1 to cruciform hairpins. J. Mol. Biol. 2005, 348:609-615.
26. Szabo C., et al. Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol. Sci. 2006, 27:626-630.
27. Kraus W.L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr. Opin. Cell Biol. 2008, 20:294-302.
28. Oliver F.J., et al. Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999, 18:4446-4454.
29. Hassa P.O., et al. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappaB coactivator function. J. Biol. Chem. 2001, 276:45588-45597.
30. Chang W.J., Alvarez-Gonzalez R. The sequence specific DNA binding of NF-κB is reversibly regulated by the automodification reaction of PARP-1. J. Biol. Chem. 2001, 276:47664-47670.
31. Chiarugi A., Moskowitz M.A. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J. Neurochem. 2003, 85:306-317.
32. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008, 7:536-557.
33. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol. 2002, 137:761-770.
34. Ha H.C., et al. Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3270-3275.
35. Valdor R., et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol. Immunol. 2008, 45:1863-1871.
36. Nirodi C., et al. A role for poly(ADP-ribose) polymerase (PARP) in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J. Biol. Chem. 2001, 276:9366-9374.
37. Aldinucci A., et al. A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J. Immunol. 2007, 179:305-312.
38. Cavone L., et al. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult. Scler. 2011, 17:794-807.
39. Ullrich O., et al. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat. Cell Biol. 2001, 3:1035-1042.
40. Kauppinen T.M., et al. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J. Neurosci. Res. 2005, 81:190-198.
41. Rapizzi E., et al. Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively up-regulates expression of proinflammatory genes. Mol. Pharmacol. 2004, 66:890-898.
42. Kauppinen T.M., Swanson R.A. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J. Immunol. 2005, 174:2288-2296.
43. Saenz L., et al. Transcriptional regulation by poly(ADP-ribose) polymerase-1 during T cell activation. BMC Genomics 2008, 9:171.
44. Weltin D., et al. Immunosuppressive activities of 6(5)-phenanthridinone, a new poly(ADP-ribose) polymerase inhibitor. Int. J. Immunopharmacol. 1995, 17:265-271.
45. Carrillo A., et al. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. Nucleic Acids Res. 2004, 32:757-766.
46. Bettelli E., et al. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 2003, 197:1073-1081.
47. Zehntner S.P., et al. Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease. FASEB J. 2003, 17:1910-1912.
48. Friese M.A., Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann. Neurol. 2009, 66:132-141.
49. Scott G.S., et al. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 2001, 117:78-86.
50. Scott G.S., et al. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 2004, 310:1053-1061.
51. Farez M.F., et al. Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE. Nat. Immunol. 2009, 10:958-964.
52. Selvaraj V., et al. PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. J. Biol. Chem. 2009, 284:26070-26084.
53. Miller S.D., et al. Experimental autoimmune encephalomyelitis in the mouse. Curr. Protoc. Immunol. 2010, 1-20. (Chapter 15, Unit 15.1).
54. Fritz R.B., Zhao M.L. Active and passive experimental autoimmune encephalomyelitis in strain 129/J (H-2b) mice. J. Neurosci. Res. 1996, 45:471-474.
55. Scott G.S., et al. Peroxynitrite-induced oligodendrocyte toxicity is not dependent on poly(ADP-ribose) polymerase activation. Glia 2003, 41:105-116.
56. King S.L., et al. Differential role for ADP-ribosylation in gene expression during the activation of T lymphocytes by various stimuli. Immunology 1989, 67:258-262.
57. Vanderlugt C.L., Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2002, 2:85-95.
58. McMahon E.J., et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
59. Shockett P., Stavnezer J. Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching. J. Immunol. 1993, 151:6962-6976.
60. Lenzser G., et al. Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J. Cereb. Blood Flow Metab. 2007, 27:1318-1326.
61. Nasta F., et al. Increased Foxp3+ regulatory T cells in poly(ADP-ribose) polymerase-1 deficiency. J. Immunol. 2010, 184:3470-3477.
62. Venken K., et al. Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends Mol. Med. 2010, 16:58-68.
63. Aktas O., et al. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010, 33:140-152.
64. Siffrin V., et al. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci. 2010, 33:202-210.
65. Centonze D., et al. The link between inflammation, synaptic transmission and neurodegeneration in multiple sclerosis. Cell Death Differ. 2010, 17:1083-1091.
66. Meli E., et al. Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage. Toxicol. Lett. 2003, 139:153-162.
67. Chiarugi A. Intrinsic mechanisms of poly(ADP-ribose) neurotoxicity: three hypotheses. Neurotoxicology 2005, 26:847-855.
68. Bailey S.L., et al. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 2007, 8:172-180.
69. Rutella S., et al. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108:1435-1440.
70. Axtell R.C., et al. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011, 32:272-277.
71. Steinman L., Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60:12-21.
72. Batoulis H., et al. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Ann. Anat. 2010, 192:179-193.
73. Libbey J.E., et al. Molecular mimicry in multiple sclerosis. Int. Rev. Neurobiol. 2007, 79:127-147.
74. Podbielska M., Hogan E.L. Molecular and immunogenic features of myelin lipids: incitants or modulators of multiple sclerosis?. Mult. Scler. 2009, 15:1011-1029.
75. Stinissen P., et al. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit. Rev. Immunol. 1997, 17:33-75.
76. Costantino C.M., et al. Multiple sclerosis and regulatory T cells. J. Clin. Immunol. 2008, 28:697-706.
77. Cua D.J., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
78. Zepp J., et al. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol. 2011, 32:232-239.
79. Stromnes I.M., et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 2008, 14:337-342.
80. Pietrowski E., et al. Pro-inflammatory effects of interleukin-17A on vascular smooth muscle cells involve NAD(P)H-oxidase derived reactive oxygen species. J. Vasc. Res. 2011, 48:52-58.
81. Izcue A., et al. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 2009, 27:313-338.
82. Valencia X., Lipsky P.E. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2007, 3:619-626.
83. McLaughlin K.A., Wucherpfennig K.W. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv. Immunol. 2008, 98:121-149.
84. Skulina C., et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2428-2433.
85. Kreft K.L., et al. Role of CD8 regulatory T-cells in multiple sclerosis. Ann. Neurol. 2011, 69:593-594.
86. Lucchinetti C., et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707-717.
87. Sellebjerg F., et al. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. J. Neuroimmunol. 1998, 84:179-187.
88. Jagtap P., Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 2005, 4:421-440.
89. Virag L., Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54:375-429.
90. Calvert H., Azzariti A. The clinical development of inhibitors of poly(ADP-ribose) polymerase. Ann. Oncol. 2011, 22(Suppl. 1):i53-i59.
91. Yap T.A., et al. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 2011, 61:31-49.
92. O'Shaughnessy J., et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2011, 364:205-214.
93. Hottiger M.O., et al. Progress in the function and regulation of ADP-ribosylation. Sci. Signal. 2011, 4:mr5.
94. Morrow D.A., et al. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis 2009, 27:359-364.
95. Wurzer G., et al. Increased resistance to anticancer therapy of mouse cells lacking the poly(ADP-ribose) polymerase attributable to up-regulation of the multidrug resistance gene product P-glycoprotein. Cancer Res. 2000, 60:4238-4244.